Elsevier

Biochemical Pharmacology

Volume 97, Issue 4, 15 October 2015, Pages 590-600
Biochemical Pharmacology

Review
The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain

https://doi.org/10.1016/j.bcp.2015.04.013Get rights and content

Abstract

The aim of the present study was to determine the impact of α5 nicotinic acetylcholine receptor (nAChR) subunit deletion in the mouse on the development and intensity of nociceptive behavior in various chronic pain models.

The role of α5-containing nAChRs was explored in mouse models of chronic pain, including peripheral neuropathy (chronic constriction nerve injury, CCI), tonic inflammatory pain (the formalin test) and short and long-term inflammatory pain (complete Freund's adjuvant, CFA and carrageenan tests) in α5 knock-out (KO) and wild-type (WT) mice.

The results showed that paw-licking time was decreased in the formalin test, and the hyperalgesic and allodynic responses to carrageenan and CFA injections were also reduced. In addition, paw edema in formalin-, carrageenan- or CFA-treated mice were attenuated in α5-KO mice significantly. Furthermore, tumor necrosis factor-alpha (TNF-α) levels of carrageenan-treated paws were lower in α5-KO mice. The antinociceptive effects of nicotine and sazetidine-A but not varenicline were α5-dependent in the formalin test. Both hyperalgesia and allodynia observed in the CCI test were reduced in α5-KO mice. Nicotine reversal of mechanical allodynia in the CCI test was mediated through α5-nAChRs at spinal and peripheral sites.

In summary, our results highlight the involvement of the α5 nAChR subunit in the development of hyperalgesia, allodynia and inflammation associated with chronic neuropathic and inflammatory pain models. They also suggest the importance of α5-nAChRs as a target for the treatment of chronic pain.

Introduction

Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that exist as homomeric or heteromeric complexes of α and β subunits. To date, 12 neuronal subunits (α2–α10 and β2–β4) have been identified in mammals [1]. The α5 nAChR subunits are widely expressed in the mammalian central nervous system [2], including the spinal cord [3], rat dorsal root ganglia [4], as well as peripherally in sympathetic and parasympathetic ganglia [5].

The α5 subunit cannot form a functional homomeric receptor, or assemble in nAChRs as the sole α subunit expressed with either β2 or β4. Therefore, the α5 subunit is incorporated into α4β2*, α3β2*, and α3β4* nAChRs (where * denotes the possible inclusion of additional nAChR subunits) where it greatly influences nicotine's modulation of receptor function and pharmacological properties of these receptor subtypes in response to the drug in heterologous expression systems [6], [7], [8]. Furthermore, recent data support an important role for α5 in nicotine's behavioral effects. Mice null for the α5 nAChR subunit have reduced sensitivity to nicotine-induced seizures and hypolocomotion [9], [10]. Additionally, these α5 KO mice are less sensitive to nicotine-induced antinociception and hypothermia compared to WT littermates after acute administration of the drug in mice [11], [12]. Interestingly, α5 KO mice showed an enhancement of nicotine reward and intake [11], [13].

Data is also emerging on the possible role of α5-containing nAChRs in the regulation of important functions in the central nervous system as well as the peripheral nervous system. For example, these receptors were reported to influence the autonomic control of several organ systems [14]. Furthermore, Vincler and Eisenach [26] observed an increased expression of the α5 nAChR subunit in the outer laminae of the dorsal horn following spinal nerve ligation in rats [3]. More recently, the same group reported that intrathecal injection of α5 antisense oligonucleotides to rats with spinal nerve ligation alleviated the mechanical allodynia in the animals [15]. In addition, treatment of these rats with α5-antisense was accompanied with a significant reduction in pCREB immunoreactivity in the outer laminae of the dorsal horn of the ligated rats. We therefore hypothesized that disruption of α5 nAChR subunit will modulate pain behaviors in chronic inflammatory and neuropathic pain.

The present study seeks to determine the impact of α5 nAChR subunit deletion in the mouse on the development and intensity of nociceptive behavior in various chronic pain models. Using α5 knock-out (KO) mice, the role of α5-containing nAChRs was explored in well-established rodent models of chronic pain, such as peripheral neuropathy (chronic constriction nerve injury, CCI), tonic inflammatory pain (the formalin test) and short- and long-term inflammatory pain (carrageenan and complete Freund's adjuvant – CFA tests). We also determined to what extent is the antinociceptive effects of nicotine, in some of these models, are mediated by α5-containing nAChRs. Data obtained from these studies will further the understanding of the α5 nAChR subunit in pain regulation and may lead to the development of α5-containing nAChR agonists for the treatment of chronic pain.

Section snippets

Animals

Male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and were used only for backcrossing. Mice null for the α5 subunit and their wild-type littermates were bred in an animal care facility at Virginia Commonwealth University (Richmond, VA) and are maintained on a C57Bl/6J background. They have been backcrossed to at least N12. For all experiments, mutants and wild type controls are obtained from crossing heterozygote mice. This breeding scheme allows us to rigorously

Pain behavior and paw edema in α5 knockout mice in the formalin test

First, we evaluated the paw licking response of α5 KO and WT mice (n = 8/each group) in the formalin test at 2.5% concentration. No significant difference was found in phase I behaviors between WT and KO animals (Fig. 1A). However, in the phase II response, there were significant reductions of pain behavior in α5 KO mice compared to WT mice [F(1,14) = 32.278 p < 0.001] (Fig. 1A). Additionally, the changes of paw edema were measured in α5 WT and KO mice 1 h after intraplantar injection of 2.5%

Discussion

Nicotine and nicotinic receptors have been explored for the past three decades as a strategy for pain control. These receptors are widely expressed throughout the central and peripheral nervous system as well as immune cells. Despite encouraging results with many α4β2* agonists in animal models of pain, human studies showed a narrow therapeutic window of these drugs. However, the lack of understanding of the composition of nicotinic receptor subtypes mediating analgesia has hampered the

Conflict of interest statement

The authors have no conflict of interest associated with this study to declare.

Acknowledgements

This work was supported by NIDA DA-12610. Deniz Bagdas would like to thank The Scientific and Technical Research Council of Turkey (TUBITAK) for her postdoctoral research scholarship (2219-2013). The authors wish to thank Tie Han, Lisa Merritt and Cindy Evans for their technical assistance and maintenance of the breeding colony. The authors wish to thank Asti Jackson for her editing of the manuscript.

References (45)

  • C.J. LaBuda et al.

    A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats

    Exp. Neurol.

    (2000)
  • K.J. Jackson et al.

    The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse

    Neuropharmacology

    (2013)
  • M.C. Rowbotham et al.

    Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain

    Pain

    (2012)
  • M.C. Rowbotham et al.

    A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain

    Pain

    (2009)
  • J.R. Genzen et al.

    Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes

    J. Neurophysiol.

    (2001)
  • M. De Biasi

    Nicotinic receptor mutant mice in the study of autonomic function

    Curr. Drug Targets CNS Neurol. Disord.

    (2002)
  • V. Gerzanich et al.

    Alpha 5 subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors

    J. Pharmacol. Exp. Ther.

    (1998)
  • J. Ramirez-Latorre et al.

    Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels

    Nature

    (1996)
  • L. Tapia et al.

    Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors

    Mol. Pharmacol.

    (2007)
  • M. Kedmi et al.

    Mice lacking neuronal nicotinic acetylcholine receptor beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to nicotine-induced seizures

    Physiol. Genomics

    (2004)
  • R. Salas et al.

    The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo

    Mol. Pharmacol.

    (2003)
  • K.J. Jackson et al.

    Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice

    J. Pharmacol. Exp. Ther.

    (2010)
  • Cited by (44)

    • Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein

      2022, Experimental Neurology
      Citation Excerpt :

      However, thermal sensitivity was only tested once every two weeks (weeks 0–22 post-DOX diet) [For Tat(−) male mice n = 11 per group and Tat(+), n = 8 per group; For Tat(−) female mice n = 11 per group and Tat(+), n = 10 per group]. Thermal heat sensitivity was determined using Hargreaves' test as previously described (Bagdas et al., 2015). Briefly, mice were placed in translucent plastic chambers (73 × 93 × 10 cm) on an elevated surface and allowed to acclimatize for 60 min to their environment before testing.

    • PCC-0105002, a novel small molecule inhibitor of PSD95-nNOS protein-protein interactions, attenuates neuropathic pain and corrects motor disorder associated with neuropathic pain model

      2021, Toxicology and Applied Pharmacology
      Citation Excerpt :

      The formalin test is a useful model, particularly for the screening of novel compounds, since it encompasses inflammatory, neurogenic and central mechanism of nociception. For this study, mice were intraperitoneally (i.p.) injected with one dose of either PCC-0105002 (10, 20, 40 mg/kg), MK-801 (0.1 mg/kg), or vehicle control (n = 14/group) 30 min prior to injection with formalin (Bagdas et al., 2015; Cazanga et al., 2018). At 10 min before formalin injection, mice were placed into a clear elevated plexiglass box to facilitate habituation.

    View all citing articles on Scopus
    1

    These authors have equally contributed to this work.

    View full text